	Area of Research	Phase 1	Phase 2	Phase 3	Post-Approval Research
MULTIPLE MYELOMA (MM)					
Lenalidomide	Relapsed/refractory	■	■	■	■
	Newly diagnosed	■	■	■	■
	Maintenance	■	■	■	■
Pomalidomide	Relapsed/refractory	■	■	■	■
Thalidomide	Newly diagnosed	■	■	■	■
ide-cel (BCMA CAR T)[a]	Relapsed/refractory[b]	■	■		
	Second-line	■	■		
	Third-line	■	■	■	
bb21217 (BCMA CAR T)[a]	Relapsed/refractory	■			
JCARH125 (BCMA CAR T)	Relapsed/refractory	■			
Iberdomide (CC-220)	Relapsed/refractory	■			
CC-92480 (CELMoD)	Relapsed/refractory	■			
CC-93269 (BCMA TCE)	Relapsed/refractory	■			
MYELODYSPLASTIC SYNDROMES (MDS)					
Azacitidine for injection		■	■	■	■
Lenalidomide	Deletion 5q	■	■	■	■
CC-486 (DNMT inhibitor)	Lower-risk	■	■	■	
	Post hypomethylating agent (HMA) failure	■	■		
Luspatercept (ACE-536)[c]	Previously treated with ESA[d]	■	■	■	
	ESA naïve	■	■	■	
ACUTE MYELOID LEUKEMIA (AML)					
Azacitidine for injection	AML (20%-30% blasts) (EU)	■	■	■	■
	AML (>30% blasts) (EU)	■	■	■	■
CC-486 (DNMT inhibitor)	Post-induction AML maintenance	■	■	■	
Enasidenib[e]	Relapsed/refractory IDH2 mutation (US)	■	■	■	■
	Newly diagnosed AML with an IDH2 mutation	■			
CC-90009 (CELMoD)	Relapsed/refractory	■			
GEM333 (CD3XCD33 Bispecific Antibody)[f]		■			
CC-95775 (BET inhibitor)		■			

[a]In collaboration with bluebird bio, Inc. bluebirdbio [b]Pivotal trial for support of regulatory submission(s).

[c]In collaboration with Acceleron Pharma, Inc. ACCELERON [d]Submission(s) pending regulatory agency review.

[e]In collaboration with Agios Pharmaceuticals, Inc. agios [f]In collaboration with GEMoaB Monoclonals GmbH. gemoab

Celgene

For information on approved uses, please refer to approved product labeling. Post-approval research includes Celgene-sponsored and Celgene-supported studies.

The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established. There is no guarantee that investigational agents or investigational uses will receive health authority approval or become commercially available in any country.

© 2019 Celgene Corporation 08/19

	Area of Research	Phase 1	Phase 2	Phase 3	Post-Approval Research
LYMPHOMA					
Lenalidomide	Mantle cell lymphoma: Relapsed/refractory	■	■	■	■
	Follicular/marginal zone lymphoma: Relapsed/refractory	■	■	■	■
Romidepsin for injection	Cutaneous T-cell lymphoma (US)	■	■	■	■
	Peripheral T-cell lymphoma: Relapsed/refractory	■	■	■	■
	Peripheral T-cell lymphoma: First-line	■	■	■	
liso-cel[a]; CD-19 (CAR T)	Diffuse large B-cell lymphoma: Third-line[b]	■	■		
	Aggressive large B-cell lymphoma: Relapsed/refractory	■	■	■	
	Diffuse large B-cell lymphoma: Second-line	■	■		
CC-486 (DNMT inhibitor)	Angioimmunoblastic T-cell lymphoma	■	■		
CC-90002 (Anti-CD47)	Non-Hodgkin lymphoma	■			
CC-90010 (BET inhibitor)	Non-Hodgkin lymphoma	■			
CC-95775 (BET inhibitor)	Non-Hodgkin lymphoma	■			
CC-99282		■			
CC-95251		■			
CC-90011		■			
CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)					
liso-cel[a]; CD-19 (CAR T)		■	■		
BETA-THALASSEMIA					
Luspatercept (ACE-536)[c]	Transfusion-dependent	■	■	■	
	Non-transfusion-dependent	■	■		
MYELOFIBROSIS (MF)					
Fedratinib		■	■	■	■
Luspatercept (ACE-536)[c]	MF anemia[d]	■	■		

[a]Lisocabtagene maraleucel. [b]Pivotal trial for support of first regulatory submission(s).

[c]In collaboration with Acceleron Pharma, Inc. ACCELERON [d]Submission(s) pending regulatory agency review.

For information on approved uses, please refer to approved product labeling. Post-approval research includes Celgene-sponsored and Celgene-supported studies.

The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established. There is no guarantee that investigational agents or investigational uses will receive health authority approval or become commercially available in any country.

© 2019 Celgene Corporation 08/19

	Area of Research	Phase 1	Phase 2	Phase 3	Post-Approval Research
SOLID TUMORS					
Paclitaxel protein-bound particles for injectable suspension (albumin-bound) (US)/paclitaxel formulated as albumin-bound nanoparticles (EU)	Breast: Metastatic				
	Non-small cell lung: Advanced (First-line)				
	Gastric: Metastatic (Japan)[a]				
Marizomib	Glioblastoma				
Motolimod/PD-1	Head and Neck				
CC-90011	Extensive stage small cell lung cancer				
CC-90010 (BET inhibitor)					
CC-95251					
Pomalidomide	GBM pediatric				
GEMoab CD3xPSCA[b]	Solid tumor				
INFLAMMATION & IMMUNOLOGY					
Apremilast	Psoriatic arthritis				
	Plaque psoriasis (Moderate to Severe)				
	Plaque psoriasis (Mild to Moderate)				
	Plaque psoriasis (Pediatric)				
	Behçet's disease				
	Scalp psoriasis[c]				
	Genital psoriasis				
Ozanimod	Relapsing multiple sclerosis[c]				
	Ulcerative colitis				
	Crohn's disease				
CC-93538	Eosinophilic esophagitis				
Iberdomide (CC-220)	Systemic lupus erythematosus				
CC-90001	Idiopathic pulmonary fibrosis				
CC-90006	Psoriasis				
CC-92252	Autoimmune				

[a]Trial conducted by licensee partner, Taiho Pharmaceuticals Co. Ltd. [b]In collaboration with GEMoaB Monoclonals GmbH.

[c]Submission(s) pending regulatory agency review.

Celgene

For information on approved uses, please refer to approved product labeling. Post-approval research includes Celgene-sponsored and Celgene-supported studies.

The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established. There is no guarantee that investigational agents or investigational uses will receive health authority approval or become commercially available in any country.

© 2019 Celgene Corporation 08/19